FindTrial
Sign In

Study of the relevance between phosphatidylcholines in plasma and the efficacy of neoadjuvant therapy for esophageal squamous cell carcinoma

Study of the relevance between phosphatidylcholines in plasma and the efficacy of neoadjuvant therapy for esophageal squamous cell carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095437
Enrollment
Unknown
Registered
2025-01-07
Start date
2025-01-13
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal squamous cell carcinoma

Interventions

Observation group:None

Sponsors

Nanyang Second General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2. Received neoadjuvant therapy and radical surgical treatment for esophageal cancer. 3. Esophageal squamous cell carcinoma was diagnosed by biopsy.

Exclusion criteria

Exclusion criteria: 1. People with a history of severe mental illness, 2. Suffering from other malignant tumors such as lung cancer.

Design outcomes

Primary

MeasureTime frame
Plasma PC concentration before and after neoadjuvant therapy for esophageal squamous cell carcinoma;—

Secondary

MeasureTime frame
cTNM stage before neoadjuvant therapy;Postoperative ypTNM staging;Tumor regression grade of esophageal squamous cell carcinoma after neoadjuvant therapy;Evaluation of target lesion before and after neoadjuvant therapy for esophageal squamous cell carcinoma;Plasma PC concentration 1 month after surgery;—

Countries

China

Contacts

Public ContactTian Yongyan

Nanyang Second General Hospital

xiaotian_12345@163.com+86 138 3779 0367

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026